CATX
Perspective Therapeutics, Inc.
Medical - Devices
Market Cap$267M
5Y Perf.-74.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CATX vs RNW
Revenue, margins, valuation, and 5-year total return — side by side.
RNW
ReNew Energy Global Plc
Renewable Utilities
Market Cap$1.33B
5Y Perf.-50.9%
CATX vs RNW — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CATX | RNW |
|---|---|---|
| Industry | Medical - Devices | Renewable Utilities |
| Market Cap | $267M | $1.33B |
| Revenue (TTM) | $576K | $129.66B |
| Net Income (TTM) | $-114M | $11.97B |
| Gross Margin | -150.2% | 77.9% |
| Operating Margin | -184.6% | 48.4% |
| Forward P/E | — | 0.4x |
| Total Debt | $4M | $732.28B |
| Cash & Equiv. | $62M | $40.42B |
CATX vs RNW — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CATX
RNW
| Stock | Feb 21 | May 26 | Return |
|---|---|---|---|
| Perspective Therape… (CATX) | 100 | 25.7 | -74.3% |
| ReNew Energy Global… (RNW) | 100 | 49.1 | -50.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CATX vs RNW
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RNW leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Perspective Therapeutics, Inc. is the stronger pick specifically for recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
CATX
Perspective Therapeutics, Inc.
The Income Pick
CATX is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 1.58
- Lower volatility, beta 1.58, Low D/E 1.4%, current ratio 12.68x
- +53.2% vs RNW's -17.7%
Best for: income & stability and sleep-well-at-night
RNW
ReNew Energy Global Plc
The Growth Play
RNW carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 19.4%, EPS growth 10.1%, 3Y rev CAGR 17.8%
- -50.5% 10Y total return vs CATX's -66.4%
- Beta 0.62, current ratio 0.60x
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RNW | 19.4% revenue growth vs CATX's -100.0% |
| Quality / Margins | RNW | 9.2% margin vs CATX's -197.3% |
| Stability / Safety | RNW | Beta 0.62 vs CATX's 1.58 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CATX | +53.2% vs RNW's -17.7% |
| Efficiency (ROA) | RNW | 1.2% ROA vs CATX's -36.6%, ROIC 4.9% vs 5.2% |
CATX vs RNW — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
CATX vs RNW — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRNWLAGGINGCATX
CATXPerspective Therapeut…
1leads
RNWReNew Energy Global P…
3leads
6 Total Categories
CATEGORYLEADERvs CATXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RNW5/5
Valuation MetricsMultiples, price ratios, and targets
CATX2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
RNW4/6
Risk & VolatilityBeta, volatility, and downside exposure
RNW2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RNW leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
RNW is the larger business by revenue, generating $129.7B annually — 225100.5x CATX's $576,000. RNW is the more profitable business, keeping 9.2% of every revenue dollar as net income compared to CATX's -197.3%.
| Metric | CATXPerspective Thera… | RNWReNew Energy Glob… |
|---|---|---|
| RevenueTrailing 12 months | $576,000 | $129.7B |
| EBITDAEarnings before interest/tax | -$104M | $86.9B |
| Net IncomeAfter-tax profit | -$114M | $12.0B |
| Free Cash FlowCash after capex | -$112M | -$23.8B |
| Gross MarginGross profit ÷ Revenue | -150.2% | +77.9% |
| Operating MarginEBIT ÷ Revenue | -184.6% | +48.4% |
| Net MarginNet income ÷ Revenue | -197.3% | +9.2% |
| FCF MarginFCF ÷ Revenue | -195.2% | -18.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +37.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.2% | +94.8% |
RNW leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
CATX leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
On an enterprise value basis, RNW's 11.3x EV/EBITDA is more attractive than CATX's 20.1x.
| Metric | CATXPerspective Thera… | RNWReNew Energy Glob… |
|---|---|---|
| Market CapShares × price | $267M | $1.3B |
| Enterprise ValueMkt cap + debt − cash | $210M | $8.6B |
| Trailing P/EPrice ÷ TTM EPS | -2.93x | 46.91x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 0.40x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 20.06x | 11.27x |
| Price / SalesMarket cap ÷ Revenue | — | 1.30x |
| Price / BookPrice ÷ Book value/share | 0.80x | 1.43x |
| Price / FCFMarket cap ÷ FCF | — | — |
CATX leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
Evenly matched — CATX and RNW each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
RNW delivers a 8.4% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $-43 for CATX. CATX carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to RNW's 5.59x.
| Metric | CATXPerspective Thera… | RNWReNew Energy Glob… |
|---|---|---|
| ROE (TTM)Return on equity | -42.8% | +8.4% |
| ROA (TTM)Return on assets | -36.6% | +1.2% |
| ROICReturn on invested capital | +5.2% | +4.9% |
| ROCEReturn on capital employed | +5.2% | +6.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 5.59x |
| Net DebtTotal debt minus cash | -$58M | $691.9B |
| Cash & Equiv.Liquid assets | $62M | $40.4B |
| Total DebtShort + long-term debt | $4M | $732.3B |
| Interest CoverageEBIT ÷ Interest expense | -948.77x | 86.76x |
Evenly matched — CATX and RNW each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
RNW leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RNW five years ago would be worth $5,427 today (with dividends reinvested), compared to $4,100 for CATX. Over the past 12 months, CATX leads with a +53.2% total return vs RNW's -17.7%. The 3-year compound annual growth rate (CAGR) favors RNW at 1.5% vs CATX's -18.7% — a key indicator of consistent wealth creation.
| Metric | CATXPerspective Thera… | RNWReNew Energy Glob… |
|---|---|---|
| YTD ReturnYear-to-date | +29.0% | -7.8% |
| 1-Year ReturnPast 12 months | +53.2% | -17.7% |
| 3-Year ReturnCumulative with dividends | -46.2% | +4.4% |
| 5-Year ReturnCumulative with dividends | -59.0% | -45.7% |
| 10-Year ReturnCumulative with dividends | -66.4% | -50.5% |
| CAGR (3Y)Annualised 3-year return | -18.7% | +1.5% |
RNW leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
RNW leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RNW is the less volatile stock with a 0.62 beta — it tends to amplify market swings less than CATX's 1.58 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RNW currently trades 65.5% from its 52-week high vs CATX's 58.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CATXPerspective Thera… | RNWReNew Energy Glob… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.58x | 0.62x |
| 52-Week HighHighest price in past year | $6.16 | $8.24 |
| 52-Week LowLowest price in past year | $1.96 | $4.38 |
| % of 52W HighCurrent price vs 52-week peak | +58.4% | +65.5% |
| RSI (14)Momentum oscillator 0–100 | 39.3 | 64.1 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 734K |
RNW leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CATX as "Buy" and RNW as "Buy". Consensus price targets imply 226.4% upside for CATX (target: $12) vs 20.7% for RNW (target: $7).
| Metric | CATXPerspective Thera… | RNWReNew Energy Glob… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $11.75 | $6.52 |
| # AnalystsCovering analysts | 11 | 6 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RNW leads in 3 of 6 categories (Income & Cash Flow, Total Returns). CATX leads in 1 (Valuation Metrics). 1 tied.
Best OverallReNew Energy Global Plc (RNW)Leads 3 of 6 categories
Loading custom metrics...
CATX vs RNW: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CATX or RNW a better buy right now?
For growth investors, ReNew Energy Global Plc (RNW) is the stronger pick with 19.
4% revenue growth year-over-year, versus -100. 0% for Perspective Therapeutics, Inc. (CATX). ReNew Energy Global Plc (RNW) offers the better valuation at 46. 9x trailing P/E (0. 4x forward), making it the more compelling value choice. Analysts rate Perspective Therapeutics, Inc. (CATX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CATX or RNW?
Over the past 5 years, ReNew Energy Global Plc (RNW) delivered a total return of -45.
7%, compared to -59. 0% for Perspective Therapeutics, Inc. (CATX). Over 10 years, the gap is even starker: RNW returned -50. 5% versus CATX's -66. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CATX or RNW?
By beta (market sensitivity over 5 years), ReNew Energy Global Plc (RNW) is the lower-risk stock at 0.
62β versus Perspective Therapeutics, Inc. 's 1. 58β — meaning CATX is approximately 154% more volatile than RNW relative to the S&P 500. On balance sheet safety, Perspective Therapeutics, Inc. (CATX) carries a lower debt/equity ratio of 1% versus 6% for ReNew Energy Global Plc — giving it more financial flexibility in a downturn.
04Which is growing faster — CATX or RNW?
By revenue growth (latest reported year), ReNew Energy Global Plc (RNW) is pulling ahead at 19.
4% versus -100. 0% for Perspective Therapeutics, Inc. (CATX). On earnings-per-share growth, the picture is similar: ReNew Energy Global Plc grew EPS 10. 1% year-over-year, compared to -44. 7% for Perspective Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CATX or RNW?
ReNew Energy Global Plc (RNW) is the more profitable company, earning 3.
9% net margin versus -197. 3% for Perspective Therapeutics, Inc. — meaning it keeps 3. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNW leads at 53. 5% versus -184. 6% for CATX. At the gross margin level — before operating expenses — RNW leads at 91. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CATX or RNW more undervalued right now?
Analyst consensus price targets imply the most upside for CATX: 226.
4% to $11. 75.
07Which pays a better dividend — CATX or RNW?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is CATX or RNW better for a retirement portfolio?
For long-horizon retirement investors, ReNew Energy Global Plc (RNW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
62)). Perspective Therapeutics, Inc. (CATX) carries a higher beta of 1. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RNW: -50. 5%, CATX: -66. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CATX and RNW?
These companies operate in different sectors (CATX (Healthcare) and RNW (Utilities)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CATX is a small-cap quality compounder stock; RNW is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(CATX: -100.0% · RNW: 37.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.